http://www.sophirisbio.com/2016/05/prospective-randomized-double-blind-vechicle-controlled-multinational-phase-3-clinical-trial-of-the-pore-forming-protein-prx302-for-the-targeted-treatment-of-symptomatic-benign-prostatic-hyperpla/